Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

The phase 2 MASTER trial used next-generation sequencing minimal residual disease to decide the duration of daratumumab, carfilzomib, lenalidomide, and dexamethasone after transplant in newly diagnosed myeloma.

Journal of Clinical OncologyPubMed 34898239DOI 10.1200/JCO.21.01935